Immunology
Autoimmune Inner Ear Disease
3
Pipeline Programs↗
1
Active Trials↗
2
Companies Involved↗
Autoimmune Inner Ear Disease is an early-stage landscape with 3 programs across 2 companies. The most active players are Johnson & Johnson, Institut de Recherches Internationales Servier.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical
No programs
Phase 11
Phase 3
No programs
Approved
No programs
Analysis
Modality Breakdown
4programs
Small molecule250%
Monoclonal antibody250%
Modality classified for 100% of 4 pipeline programs.
Analysis
Trial Status
4
clinical trials
Completed2 · 50%
Recruiting1 · 25%
Terminated1 · 25%
Clinical Trials
Trial Activity
Intratympanic Injection for Autoimmune Inner Ear Disease
Terminated·—·Phase 1/2·NCT01526174·16 enrolled
A Clinical Trial of Anakinra for Steroid-Resistant Autoimmune Inner Ear Disease
Completed·—·Phase 1/2·NCT01267994·13 enrolled
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)